​

NeoGenomics (NEO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NEO Stock Forecast

NeoGenomics (NEO) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $18.00, with a high of $18.00 and a low of $18.00. This represents a 88.48% increase from the last price of $9.55.

$9 $10 $11 $12 $13 $14 $15 $16 $17 $18 High: $18 Avg: $18 Low: $18 Last Closed Price: $9.55

NEO Stock Rating

NeoGenomics stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 1 Strong Buy (3.70%), 21 Buy (77.78%), 4 Hold (14.81%), 1 Sell (3.70%), and 0 Strong Sell (0.00%).

Buy
Total 27 1 4 21 1 Strong Sell Sell Hold Buy Strong Buy

NEO Price Target Upside V Benchmarks

TypeNameUpside
StockNeoGenomics88.48%
SectorHealthcare Stocks 35.94%
IndustryDiagnostics & Research Stocks48.52%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$19.33
Last Closing Price$9.55$9.55$9.55
Upside/Downside--102.41%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25374--14
Mar, 25374--14
Feb, 25374--14
Jan, 25384--15
Dec, 24383--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 11, 2025Mark MassaroBTIG$18.00$14.7721.87%88.48%
Jul 30, 2024Mike MatsonNeedham$19.00$14.6429.78%98.95%
May 02, 2024Mark MassaroBTIG$21.00$13.9650.43%119.90%
Aug 21, 2023Mason CarricoStephens$18.00$14.0827.84%88.48%
Aug 17, 2022David WestenbergPiper Sandler$19.00$11.6463.23%98.95%
Aug 10, 2022Morgan Stanley$18.00$11.6654.37%88.48%
Aug 10, 2022Goldman Sachs$20.00$11.5972.56%109.42%
Aug 10, 2022Needham$16.00$11.6836.99%67.54%
Apr 28, 2022Raymond James$15.00$10.4443.68%57.07%
Jun 03, 2021Matthew SykesGoldman Sachs$55.00$40.1137.12%475.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 11, 2025BTIGBuyBuyhold
Sep 24, 2024StephensBuyBuyhold
Sep 24, 2024BenchmarkBuyBuyhold
Jul 30, 2024NeedhamBuyBuyhold
May 02, 2024BTIGBuyBuyhold
Mar 18, 2024Piper SandlerBuyBuyhold
Feb 22, 2024Goldman SachsBuyBuyhold
Feb 21, 2024NeedhamBuyBuyhold
Dec 29, 2023Cowen & Co.OutperformOutperformhold
Dec 28, 2023Piper SandlerBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$0.04$-0.07$-1.16$-0.70$-0.62---
Avg Forecast$0.07$-0.27$-0.68$-0.17$0.10$0.20$0.36$0.51
High Forecast$0.07$-0.27$-0.67$-0.16$0.12$0.24$0.54$0.51
Low Forecast$0.07$-0.27$-0.69$-0.20$0.09$0.13$0.13$0.50
Surprise %-42.86%-74.07%70.59%311.76%-720.00%---

Revenue Forecast

$400M $510M $620M $730M $840M $950M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$444.45M$484.33M$509.73M$591.64M$660.57M---
Avg Forecast$443.80M$484.65M$501.06M$588.86M$661.89M$733.08M$806.77M$863.51M
High Forecast$446.80M$487.93M$505.90M$591.66M$664.30M$735.03M$807.37M$904.01M
Low Forecast$440.47M$481.01M$495.67M$584.96M$660.51M$731.17M$806.17M$823.01M
Surprise %0.15%-0.07%1.73%0.47%-0.20%---

Net Income Forecast

$-250M $-180M $-110M $-40M $30M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$4.17M$-8.35M$-144.25M$-87.97M$-78.73M---
Avg Forecast$-15.11M$-77.40M$-167.24M$-87.97M$13.05M$23.19M$42.38M$64.01M
High Forecast$-6.67M$-20.95M$-133.79M$-70.37M$15.11M$30.09M$68.11M$64.44M
Low Forecast$-23.56M$-133.85M$-200.68M$-105.56M$10.99M$16.30M$16.65M$63.35M
Surprise %-127.60%-89.22%-13.74%--703.26%---

NEO Forecast FAQ

Is NeoGenomics stock a buy?

NeoGenomics stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 21 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that NeoGenomics is a favorable investment for most analysts.

What is NeoGenomics's price target?

NeoGenomics's price target, set by 27 Wall Street analysts, averages $18 over the next 12 months. The price target range spans from $18 at the low end to $18 at the high end, suggesting a potential 88.48% change from the previous closing price of $9.55.

How does NeoGenomics stock forecast compare to its benchmarks?

NeoGenomics's stock forecast shows a 88.48% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the diagnostics & research stocks industry (48.52%).

What is the breakdown of analyst ratings for NeoGenomics over the past three months?

  • April 2025: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.

What is NeoGenomics’s EPS forecast?

NeoGenomics's average annual EPS forecast for its fiscal year ending in December 2025 is $0.2, marking a -132.26% decrease from the reported $-0.62 in 2024. Estimates for the following years are $0.36 in 2026, and $0.51 in 2027.

What is NeoGenomics’s revenue forecast?

NeoGenomics's average annual revenue forecast for its fiscal year ending in December 2025 is $733.08M, reflecting a 10.98% increase from the reported $660.57M in 2024. The forecast for 2026 is $806.77M, and $863.51M for 2027.

What is NeoGenomics’s net income forecast?

NeoGenomics's net income forecast for the fiscal year ending in December 2025 stands at $23.19M, representing a -129.46% decrease from the reported $-78.726M in 2024. Projections indicate $42.38M in 2026, and $64.01M in 2027.